Raison CL

Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53719, USA.

4 preprints · 14 papers · ORCID

PreprintPsychedelics

The Allostatic Reset Model (ARM) of Psychedelic Action

Lawrence D, Brouwer A, Fabiano N +2

Europe PMC2026
ArticlePsilocybin

Electrophysiological effects of psilocybin co-administered with midazolam.

Sutherland MH, Nicholas CR, Lennertz RC +8

Europe PMC2026
ArticleDMT

Reactivations Associated with the Use of 5-MeO-DMT Among Spanish-Speaking Individuals: Prevalence, Predictors, and Emotional Valence.

Ortiz Bernal AM, Raison CL, Lancelotta RL +3

Europe PMC2025
PreprintPsilocybin

Electrophysiological effects of psilocybin co-administered with midazolam

Sutherland MH, Nicholas CR, Lennertz RC +8

Europe PMC2025
ArticlePsilocybin

A qualitative analysis of the psychedelic mushroom come-up and come-down.

Brouwer A, Brown JK, Erowid E +4

Europe PMC2025
ArticlePsilocybin

Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience.

Nicholas CR, Banks MI, Lennertz RC +9

Europe PMC2024
ArticlePsychedelics

Psychotomimetic compensation versus sensitization.

Brouwer A, Carhart-Harris RL, Raison CL

Europe PMC2024
ArticlePsilocybin

Psilocybin desynchronizes the human brain.

Siegel JS, Subramanian S, Perry D +30

Europe PMC2024
PreprintPsilocybin

Co-administration of midazolam and psilocybin: Differential effects on subjective quality versus memory of the psychedelic experience

Nicholas CR, Banks MI, Lennertz RL +9

Europe PMC2024
PreprintPsilocybin

The Temporal Trajectory of the Psychedelic Mushroom Experience Mimics the Narrative Arc of the Hero’s Journey

Brouwer A, Brown JK, Erowid E +4

Europe PMC2024
ArticlePsychedelics

Spiritual health practitioners' contributions to psychedelic assisted therapy: A qualitative analysis.

Peacock C, Mascaro JS, Brauer E +7

Europe PMC2024
ArticlePsilocybin

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.

Raison CL, Sanacora G, Woolley J +31

Europe PMC2023
ArticlePsilocybin

Psychedelics, With a Focus on Psilocybin: Issues for the Clinician.

Garakani A, Alexander JL, Sumner CR +5

Europe PMC2023
ArticlePsychedelics

Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review.

Kiluk BD, Kleykamp BA, Comer SD +24

Europe PMC2023
ArticleDMT

Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon's predictors and its emotional valence.

Ortiz Bernal AM, Raison CL, Lancelotta RL +1

Europe PMC2022
ArticleMDMA

Toward Risk-Benefit Assessments in Psychedelic- and MDMA-Assisted Therapies.

Bradberry MM, Gukasyan N, Raison CL

Europe PMC2022
ArticlePsilocybin

Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States.

Raison CL, Jain R, Penn AD +2

Europe PMC2022
ArticlePsilocybin

Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.

Goldberg SB, Shechet B, Nicholas CR +4

Europe PMC2020